STOCK TITAN
  1. Home
  2. Sec-filings
  3. NAMS
  4. [8-K] NewAmsterdam Pharma Co N.V. Reports Material Event

NewAmsterdam Pharma (NAMS) hires Robert Gunning as new principal accounting officer

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

NewAmsterdam Pharma Company N.V. appointed Robert W. Gunning, 55, as principal accounting officer effective August 10, 2026, succeeding Louise Kooij, whose departure effective August 31, 2026 had been previously announced. Gunning joined as Vice President, Controller on the same date, bringing prior senior finance and controller experience at several biopharmaceutical and biotechnology companies.

Under a July 24, 2026 offer letter with a wholly owned subsidiary, Gunning will receive a $375,000 annual base salary and be eligible for an annual performance bonus targeted at 30% of base salary, prorated for his first year and subject to board discretion. He will also be granted 3,200 restricted stock units and a stock option to purchase 14,000 ordinary shares under the 2024 Inducement Plan. The company states he has no disclosable related-party relationships or material interests in company transactions beyond standard indemnification arrangements.

Positive

  • None.

Negative

  • None.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Base salary $375,000 per year Annual base salary for principal accounting officer under July 24, 2026 offer letter
Bonus target 30% of base salary Target annual performance bonus percentage, prorated for first year
Restricted stock units 3,200 ordinary shares RSU award under the 2024 Inducement Plan for new hire
Stock options 14,000 ordinary shares Stock option grant under the 2024 Inducement Plan for new hire
Age 55 Age of newly appointed principal accounting officer
Effective date of appointment August 10, 2026 Date Robert W. Gunning was appointed principal accounting officer
principal accounting officer financial
"appointed Robert W. Gunning, age 55, as its principal accounting officer"
The Principal Accounting Officer is the person responsible for making sure a company's financial records are accurate and follow the rules. They play a key role in preparing financial reports that show how well the company is doing. This helps investors, managers, and regulators trust the company's financial information.
restricted stock unit award financial
"will also receive a restricted stock unit award covering 3,200 of the Company’s ordinary shares"
A restricted stock unit award is a promise by a company to give an employee a specified number of company shares at a future date if certain conditions are met, such as staying with the company or hitting performance goals. For investors, these awards matter because they can increase the total number of shares outstanding when converted, diluting existing holders, and they align employees’ incentives with shareholders’ interests much like giving a rising bonus that becomes real only after conditions are satisfied.
Inducement Plan financial
"each to be granted pursuant to the Company’s 2024 Inducement Plan"
An inducement plan is a program a company creates to encourage employees or new hires to stay or join by offering special benefits or rewards. It’s like a company giving extra bonuses or perks to persuade someone to choose their job over others, helping the company attract and keep talented workers.
Item 404(a) of Regulation S-K regulatory
"transaction that would require disclosure under Item 404(a) of Regulation S-K"
indemnification agreements regulatory
"standard indemnification agreements that the Company enters into with each of its directors"
Indemnification agreements are contracts in which one party agrees to pay for losses, legal costs, or damages another party might face — like a friend promising to cover repair bills if their dog breaks your window. For investors, these agreements matter because they determine who ultimately bears financial and legal risk, affecting a company’s potential liabilities, cash flow needs, and the willingness of executives or partners to take on roles or deals.

FAQ

What executive change did NewAmsterdam Pharma (NAMS) disclose on August 10, 2026?
NewAmsterdam Pharma appointed Robert W. Gunning as its principal accounting officer effective August 10, 2026, succeeding Louise Kooij, whose departure effective August 31, 2026 had been previously announced.

What is the base salary for NewAmsterdam Pharma’s (NAMS) new principal accounting officer?
Robert W. Gunning’s annual base salary is $375,000. He is also eligible for an annual performance bonus with a 30% target of base salary, prorated for his first year and subject to board discretion.

What equity awards will Robert W. Gunning receive from NewAmsterdam Pharma (NAMS)?
Gunning will receive a restricted stock unit award for 3,200 ordinary shares and a stock option to purchase 14,000 ordinary shares, each granted under NewAmsterdam Pharma’s 2024 Inducement Plan and aligned with standard new hire equity practices.

What prior experience does NewAmsterdam Pharma’s (NAMS) new principal accounting officer have?
Before joining, Gunning was Interim Controller at Altimmune, and previously held senior finance and controller roles at Y-mAbs Therapeutics, Excision Biotherapeutics, and Advanced Accelerator Applications USA, and holds a bachelor of business administration from Pace University.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →
false000193625800-00000000001936258us-gaap:WarrantMember2026-08-102026-08-1000019362582026-08-102026-08-100001936258us-gaap:CommonStockMember2026-08-102026-08-10

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 10, 2026

 

 

NewAmsterdam Pharma Company N.V.

(Exact name of Registrant as Specified in Its Charter)

 

 

The Netherlands

001-41562

N/A

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

Goomieer 2-35

 

Naarden

 

 

The Netherlands

 

1411 DC

(Address of Principal Executive Offices)

 

(Zip Code)

 

+31 (0) 35 206 2971

 

(Registrant’s Telephone Number, Including Area Code)

 

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Ordinary shares, nominal value €0.12 per share

 

NAMS

 

The Nasdaq Stock Market LLC

Warrants to purchase ordinary shares

 

NAMSW

 

The Nasdaq Stock Market LLC

 

☐

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On August 10, 2026, NewAmsterdam Pharma Company N.V. (the “Company”) appointed Robert W. Gunning, age 55, as its principal accounting officer. Mr. Gunning succeeds Louise Kooij, whose departure from the Company effective August 31, 2026, was previously announced, in such capacity. Mr. Gunning joined the Company as Vice President, Controller, on August 10, 2026. Prior to joining the Company, Mr. Gunning served as Interim Controller and a consultant on other financial and accounting matters to Altimmune, Inc., a biopharmaceutical company, from April 2026 until July 2026. From April 2022 until April 2026, Mr. Gunning served as Vice President Finance and Corporate Controller at Y-mAbs Therapeutics, Inc., a biopharmaceutical company, that was acquired by SERB Pharmaceuticals, a global specialty pharmaceutical company. From August 2021 until April 2022, he served as Vice President, Controller at Excision Biotherapeutics, Inc., a biotechnology company, and prior to that, he served as Chief Financial Officer (US) at Advanced Accelerator Applications USA, Inc., a pharmaceutical company owned by Novartis. Mr. Gunning holds a bachelor of business administration degree from Pace University.

 

Pursuant to an offer letter (the “Offer Letter”) dated July 24, 2026, between Mr. Gunning and NewAmsterdam Pharma Corporation, a wholly-owned subsidiary of the Company, Mr. Gunning’s base salary will be $375,000 per year, and he will be eligible for an annual performance bonus with a target amount of 30% of his base salary under the Company’s cash bonus plan, prorated for his first partial year of employment and subject to the discretion of the Company’s Board of Directors. Pursuant to the Offer Letter, Mr. Gunning will also receive a restricted stock unit award covering 3,200 of the Company’s ordinary shares and a stock option to purchase 14,000 ordinary shares, each to be granted pursuant to the Company’s 2024 Inducement Plan and in accordance with the Company’s standard new hire equity granting practices. The foregoing description of the Offer Letter is a summary only and is qualified by reference in its entirety to the Offer Letter, a copy of which the Company intends to file with its Quarterly Report on Form 10-Q for the quarter ending September 30, 2026.

 

Mr. Gunning has no family relationships with any of the Company’s directors or executive officers. There is no arrangement or understanding between Mr. Gunning and any other person pursuant to which Mr. Gunning was selected as an officer. Mr. Gunning has no direct or indirect material interest in any existing or currently proposed transaction that would require disclosure under Item 404(a) of Regulation S-K beyond the standard indemnification agreements that the Company enters into with each of its directors and principal officers providing for procedures for indemnification and advancements by the Company of certain expenses and costs relating to claims, suits or proceedings arising from his or her service to the Company or, at the Company’s request, service to other entities, as officers or directors, to the maximum extent permitted by Dutch law and subject to the exceptions provided in such agreements.

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

NewAmsterdam Pharma Company N.V.

 

 

 

 

Date:

August 14, 2026

By:

/s/ Mike Marino

 

 

Name:

Mike Marino

 

 

Title:

Chief Legal Officer

 

 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

1 document

Other Documents